{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:59:41Z","timestamp":1787759981696,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>People with migraine may prefer over-the-counter (OTC) drugs because of multiple reasons, but their overuse can cause medication overuse headaches. This analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study describes the real-world use of OTC headache drugs and the challenges that potentially prevent people with migraine from accessing appropriate medical management in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This analysis of the cross-sectional, population-based, nationwide online survey included adults with migraine. Respondents reported their experiences with prescription and OTC drugs for migraine, migraine-specific drug awareness, and attitude towards migraine. Subgroup analyses were performed based on the number of monthly headache days (MHD) and the frequency of OTC drug use\/month.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The 19,590 respondents with migraine (68.8% female; mean [SD] age 40.5 [13.1] years) had mean (SD) 3.5 (5.2) MHDs; 29.0% consulted doctors in the past year for migraine. OTC drug use in the past year was common (\u2265\u200962.1%) regardless of doctor consultation or number of MHDs. Among respondents who answered that they would usually use prescribed drugs when they have a migraine attack, 35.2% reported that they would typically use OTC drugs too. The frequency of OTC drug use was the same or higher than that of prescribed drugs in 51.3% of the respondents who consulted doctors in the past year. Only 14.6% of respondents discussed OTC drugs with doctors during consultations in the past year. Migraine-specific drug access and awareness were limited even among frequent OTC drug users (\u2265\u200910 days\/month); 18.2% used triptans, but 65.5% never heard of it. Among 37.1% of respondents who had hesitated to visit a doctor, \u2018I could handle it myself with OTC medicine\u2019 was the most common reason for hesitation (34.9%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>OTC drug use is common among people with migraine; however, it is not frequently discussed with doctors. Many respondents, even those with frequent OTC drug use, did not have access or awareness of migraine-specific drugs. To prevent medication overuse for migraine, the use of OTC drugs should also be discussed and managed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10194-025-02046-8","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T07:04:25Z","timestamp":1746601465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world use of over-the-counter medications by patients with migraine in Japan: results from the OVERCOME (Japan) 2nd study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ryotaro","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moemi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Osaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2046_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, Mori M, Kawashima M, Kowa H, Adachi Y et al (2004) Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44:8\u201319","journal-title":"Headache"},{"key":"2046_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17:15\u201322","journal-title":"Cephalalgia"},{"key":"2046_CR3","unstructured":"Institute of Medical Studies (2021) Headache Practice Guidelines 2021 [in Japanese]. 512 p. Available from: https:\/\/www.neurology-jp.org\/guidelinem\/pdf\/headache_medical_2021.pdf"},{"key":"2046_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, Han Y, Jaffe DH, Matsumori Y, Takeshima T (2021) Comprehensive population-based survey of migraine in Japan: results of the observational survey of the epidemiology, tReatment, and care of migraine (OVERCOME [Japan]) study. Curr Med Res Opin 37:1945\u20131955","journal-title":"Curr Med Res Opin"},{"key":"2046_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/j.1468-2982.2008.01731.x","volume":"28","author":"K Ravishankar","year":"2008","unstructured":"Ravishankar K (2008) Medication overuse headache in India. Cephalalgia 28:1223\u20131226","journal-title":"Cephalalgia"},{"key":"2046_CR6","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, Matsumori Y, Hirata K (2022) Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther 39:5176\u20135190","journal-title":"Adv Ther"},{"key":"2046_CR7","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1007\/s10072-021-05831-w","volume":"43","author":"M Katsuki","year":"2022","unstructured":"Katsuki M, Yamagishi C, Matsumori Y, Koh A, Kawamura S, Kashiwagi K, Kito T, Entani A, Yamamoto T, Ikeda T, Yamagishi F (2022) Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city-Itoigawa study. Neurol Sci 43:3811\u20133822","journal-title":"Neurol Sci"},{"key":"2046_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/clinpract12050074","volume":"12","author":"M Alshareef","year":"2022","unstructured":"Alshareef M (2022) Factors associated with Over-the-Counter analgesic overuse among individuals experiencing headache. Clin Pract 12:714\u2013722","journal-title":"Clin Pract"},{"key":"2046_CR9","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1-211"},{"key":"2046_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N (2024) Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain 25:19","journal-title":"J Headache Pain"},{"key":"2046_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0277-9536(00)00341-5","volume":"53","author":"B Sleath","year":"2001","unstructured":"Sleath B, Rubin RH, Campbell W, Gwyther L, Clark T (2001) Physician-patient communication about over-the-counter medications. Soc Sci Med 53:357\u2013369","journal-title":"Soc Sci Med"},{"key":"2046_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1526-4610.2004.t01-4-04020.x","volume":"44","author":"K Kotani","year":"2004","unstructured":"Kotani K, Shimomura T, Ikawa S, Sakane N, Ishimaru Y, Adachi S (2004) Japanese with headache: suffering in silence. Headache 44:108\u2013109","journal-title":"Headache"},{"key":"2046_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency (2024) List of Approved Drugs April 2004 to January 2024. Available via https:\/\/www.pmda.go.jp\/files\/000272313.pdf. Accessed March 03, 2025"},{"key":"2046_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, Ishii R, Hamakawa M, Tanizawa Y, Osaga S, Komori M (2025) The impact of migraine on the whole life course of patients: results from the OVERCOME (Japan) 2nd study. Neurol Ther 14:335\u2013356","journal-title":"Neurol Ther"},{"key":"2046_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the united States: data from the American migraine study II. Headache 41:646\u2013657","journal-title":"Headache"},{"key":"2046_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1468-2982.2006.01275.x","volume":"27","author":"S Silberstein","year":"2007","unstructured":"Silberstein S, Loder E, Diamond S, Reed ML, Bigal ME, Lipton RB, Group AA (2007) Probable migraine in the united States: results of the American migraine prevalence and prevention (AMPP) study. Cephalalgia 27:220\u2013229","journal-title":"Cephalalgia"},{"key":"2046_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-023-01623-z","volume":"24","author":"J Pascual","year":"2023","unstructured":"Pascual J, Panni T, Dell\u2019Agnello G, Gonderten S, Novick D, Evers S (2023) Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. J Headache Pain 24:88","journal-title":"J Headache Pain"},{"key":"2046_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE, Buse DC, Shapiro RE, Ashina S, Cambron-Mellott MJ et al (2022) Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache 62:122\u2013140","journal-title":"Headache"},{"key":"2046_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1526-4610.2003.03069.x","volume":"43","author":"M Iigaya","year":"2003","unstructured":"Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF (2003) Reliability and validity of the Japanese migraine disability assessment (MIDAS) questionnaire. Headache 43:343\u2013352","journal-title":"Headache"},{"key":"2046_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr., Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963\u2013974","journal-title":"Qual Life Res"},{"key":"2046_CR21","first-page":"A89","volume":"68","author":"D Buse","year":"2007","unstructured":"Buse D, Bigal MB, Rupnow M, Reed M, Serrano D, Lipton R (2007) Development and validation of the migraine interictal burden scale (MIBS): A self-administered instrument for measuring the burden of migraine between attacks. Neurology 68:A89","journal-title":"Neurology"},{"key":"2046_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422\u2013435","journal-title":"Mayo Clin Proc"},{"key":"2046_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40122-024-00589-3","volume":"13","author":"S Evers","year":"2024","unstructured":"Evers S, Dell\u2019Agnello G, Novick D, Gonderten HS, Panni T, Pascual J (2024) Acute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the OVERCOME (EU) observational study. Pain Ther 13:589\u2013607","journal-title":"Pain Ther"},{"key":"2046_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s10194-022-01439-3","volume":"23","author":"F Sakai","year":"2022","unstructured":"Sakai F, Hirata K, Igarashi H, Takeshima T, Nakayama T, Sano H, Kondo H, Shibasaki Y, Koga N (2022) A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan. J Headache Pain 23:70","journal-title":"J Headache Pain"},{"key":"2046_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pmedr.2017.12.009","volume":"9","author":"H Takaki","year":"2018","unstructured":"Takaki H, Onozuka D, Hagihara A (2018) Migraine-preventive prescription patterns by physician specialty in ambulatory care settings in the united States. Prev Med Rep 9:62\u201367","journal-title":"Prev Med Rep"},{"key":"2046_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s41983-021-00371-8","volume":"57","author":"M Fathy","year":"2021","unstructured":"Fathy M, ElSadek A, Farag S, Helmy S, AbdElMoneim A (2021) Dilemma of migraine diagnosis and management among non-neurologists. Egypt J Neurol Psychiatry Neurosurg 57:118","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"2046_CR27","unstructured":"Beithon J, Gallenberg M, Johnson K, K P, Liebow JK, Linbo M, Myers L, Peterson C, Schmidt S, Swanson J J. Diagnosis and treatment of headache: health care guideline. Bloomington, MN: Institute for Clinical Systems Improvement; 2013 December 19, 2024]. Available from: https:\/\/www.icsi.org\/guidelines__more\/catalog_guidelines_and_more\/catalog_guidelines\/catalog_neurological_guidelines\/headache\/"},{"key":"2046_CR28","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/papr.12243","volume":"15","author":"C Dougherty","year":"2015","unstructured":"Dougherty C, Silberstein SD (2015) Providing care for patients with chronic migraine: diagnosis, treatment, and management. Pain Pract 15:688\u2013692","journal-title":"Pain Pract"},{"key":"2046_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-023-01652-8","volume":"24","author":"G Vaghi","year":"2023","unstructured":"Vaghi G, De Icco R, Tassorelli C, Goadsby PJ, Vicente-Herrero T, de la Torre ER (2023) Who cares about migraine? Pathways and hurdles in the European region - access to care III. J Headache Pain 24:120","journal-title":"J Headache Pain"},{"key":"2046_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, Takeshima T, Hirata K (2022) Burden of migraine in Japan: results of the observational survey of the epidemiology, tReatment, and care of migraine (OVERCOME [Japan]) study. Neurol Ther 11:205\u2013222","journal-title":"Neurol Ther"},{"key":"2046_CR31","doi-asserted-by":"publisher","first-page":"1271438","DOI":"10.3389\/fpain.2023.1271438","volume":"4","author":"Y Karasawa","year":"2023","unstructured":"Karasawa Y, Yamaguchi K, Nakano S, Nozawa K, Iseki M (2023) Barriers to healthcare access in patients with chronic pain or potential migraine in Japan: a cross-sectional internet survey. Front Pain Res (Lausanne) 4:1271438","journal-title":"Front Pain Res (Lausanne)"},{"key":"2046_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","volume":"12","author":"J Pascual","year":"2023","unstructured":"Pascual J, Nunez M, Panni T, Diaz-Cerezo S, Novick D, Ciudad A (2023) Burden and unmet needs in migraine patients: results from the OVERCOME (Spain) study. Pain Ther 12:1209\u20131220","journal-title":"Pain Ther"},{"key":"2046_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, Azuma Y, Dodick DW (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22:29","journal-title":"J Headache Pain"},{"key":"2046_CR34","doi-asserted-by":"publisher","first-page":"e3547","DOI":"10.1002\/brb3.3547","volume":"14","author":"H Igarashi","year":"2024","unstructured":"Igarashi H, Komori M, Ueda K, Zagar AJ, Jaffe DH, Matsumori Y, Takeshima T, Hirata K (2024) Underrecognition of migraine-related stigmatizing attitudes and social burden: results of the OVERCOME Japan study. Brain Behav 14:e3547","journal-title":"Brain Behav"},{"key":"2046_CR35","doi-asserted-by":"publisher","first-page":"e077686","DOI":"10.1136\/bmjopen-2023-077686","volume":"14","author":"H Igarashi","year":"2024","unstructured":"Igarashi H, Sano H, Kondo H, Shibasaki Y, Koga N (2024) Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan. BMJ Open 14:e077686","journal-title":"BMJ Open"},{"key":"2046_CR36","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s40120-023-00545-x","volume":"12","author":"AS Dissing","year":"2023","unstructured":"Dissing AS, Lee XY, Osterberg O, Hammer-Helmich L (2023) Burden of medication overuse in migraine: A Cross-sectional, Population-Based study in five European countries using the 2020 National health and wellness survey (NHWS). Neurol Ther 12:2053\u20132065","journal-title":"Neurol Ther"},{"key":"2046_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR, Adams AM, Lipton RB (2021) Medication overuse and headache burden: results from the cameo study. Neurol Clin Pract 11:216\u2013226","journal-title":"Neurol Clin Pract"},{"key":"2046_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Greisman JD, Baigi K, Lipton RB (2019) Migraine progression: A systematic review. Headache 59:306\u2013338","journal-title":"Headache"},{"key":"2046_CR39","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/head.12201","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML (2013) Impact of NSAID and Triptan use on developing chronic migraine: results from the American migraine prevalence and prevention (AMPP) study. Headache 53:1548\u20131563","journal-title":"Headache"},{"key":"2046_CR40","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48:1157\u20131168","journal-title":"Headache"},{"key":"2046_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, Toom K, Vandervorst F, Quintana S, Paemeleire K, Katsarava Z (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19:50","journal-title":"J Headache Pain"},{"key":"2046_CR42","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2169\/internalmedicine.1471-22","volume":"62","author":"Y Ito","year":"2023","unstructured":"Ito Y, Mitsufuji T, Okada M, Fujita S, Yokoyama R, Kawasaki H, Yamamoto T (2023) Early effect of calcitonin Gene-related peptide monoclonal antibodies in migraine with medication overuse: A Single-center retrospective study. Intern Med 62:3455\u20133460","journal-title":"Intern Med"},{"key":"2046_CR43","first-page":"818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R (2022) Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the united States. J Manag Care Spec Pharm 28:818\u2013829","journal-title":"J Manag Care Spec Pharm"},{"key":"2046_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-024-01737-y","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Watanabe N, Takemura R, Takahashi N, Miyazaki N, Shibata M, Suzuki K, Imai N, Suzuki N et al (2024) CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain 25:39","journal-title":"J Headache Pain"},{"key":"2046_CR45","unstructured":"Versijpt J, Amin F, Deligianni C, Gil-Gouveia R, Martelletti P, Uluduz D, Reuter U, Sacco S, Sanchez del Rio M, van den Brink AM, Lampl C (2023) Reimbursement rules for CGRP mAbs throughout Europe. An overview of the various constraints used. Available via https:\/\/www.cgrpforum.org\/wp-content\/uploads\/Reimbursement-Europe.jpg. Accessed March 12, 2025"},{"key":"2046_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"AH Society","year":"2019","unstructured":"American Headache Society (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain 59:1\u201318","journal-title":"Headache: J Head Face Pain"},{"key":"2046_CR47","unstructured":"Insurance\u2019s Impact on Patient Access to Migraine Treatment (2025) Available via https:\/\/static1.squarespace.com\/static\/5886319ba5790a66cf05d235\/t\/65f9fc4ec4e17d65f19b48c3\/1710881873681\/SurveySummaryReportMM-HMPF-March2024.pdf. Accessed March 12"},{"key":"2046_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, Reuter U, Raffaelli B (2023) Impact of a reimbursement policy change on treatment with erenumab in migraine \u2013 a real-world experience from Germany. J Headache Pain 24:144","journal-title":"J Headache Pain"},{"key":"2046_CR49","unstructured":"How to Choose Over-the-Counter Pain Relievers and Fever Reducers (2025) Available via https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00404.html. Accessed March 26"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02046-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02046-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02046-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:03:25Z","timestamp":1746605005000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02046-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2046"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02046-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on April 19, 2023. This study was conducted per ethical principles originating from the Declaration of Helsinki and that was consistent with Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. All survey respondents provided electronic informed consent and agreed to participate in the study. All data were anonymized before analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RI received consulting fees from Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd; speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. TT is a consultant\/advisor and\/or serves on an advisory board for Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., UCB Japan Co., Ltd., Takeda Pharmaceutical Company Ltd., and Santen Pharmaceutical, a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura & Co., outside the submitted work. SS received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. DD serves on the advisory boards of and received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. MM is an employee of Social Survey Research Information Co., Ltd. Social Survey Research Information Co., Ltd. performed data collection and statistical analyses in this study and was sponsored by Eli Lilly Japan K.K. YT, SO, CH, and MK are employees of Eli Lilly Japan K.K. and may own stock\/stock options of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}